| 1. | Comparison the effects of recombinant streptokinase and urokinase in acute myocardial infarction
尿激酶对急性心肌梗死溶栓的疗效分析 |
| 2. | Comparison of therapy with recombinant streptokinase and urokinase for acute myocardial infarction
尿激酶溶栓治疗急性心肌梗死的对比研究 |
| 3. | We conducted a trial to clarify the therapeutic role of intrapleural streptokinase
我们进行了一项试验，以阐明胸膜腔内应用链激酶的治疗作用。 |
| 4. | Therapeutic efficacy of recombinant streptokinase and urokinase in the treatment of acute myocardial infarction
重组链激酶与尿激酶治疗急性心肌梗死的疗效 |
| 5. | Intrapleural streptokinase for pleural infection a step forward in managing pleural effusions
胸膜腔内滴注链激酶治疗胸膜腔感染这是胸膜腔积液治疗的进步吗 |
| 6. | The comparison of the repass rate between homemade recombined streptokinase and urokinase in thrombolytic therapy of acute myocardial infarction
国产重组链激酶与尿激酶在急性心肌梗死溶栓中的血管再通率的比较 |
| 7. | Conclusions the intrapleural administration of streptokinase does not improve mortality , the rate of surgery , or the length of the hospital stay among patients with pleural infection
结论在胸膜感染的病人中，链激酶胸膜腔内给药不能改善死亡率、手术率或住院时间的长短。 |
| 8. | The systemic administration of heparin , warfarin or streptokinase is determined to have a thrombolytic effect but risk systemic or ocular bleeding and appeare to be unhelpul for improving visual acuity
全身应用肝素、华法令或链激酶溶栓药物已被证实对提高视力没有明确帮助，并且存在全身或局部出血的风险。 |
| 9. | The quest continues for plasminogen activators with higher potency , specific thrombolytic activity , fibrin selectivity and longer half - life time . the recent progress in the protein engineering of plasminogen activators , including t - pa , u - pa , streptokinase , staphylokinase and other novel plasminogen activators , was presented in this article
一些pa突变体及新型溶栓剂，如k2p tnk - pa和star等的临床实验结果表明它们在延长体内半寿期增强对血纤维蛋白选择性和溶栓效率等方面有较大的改进。 |
| 10. | All the currently used thrombolytic agents are plasminogen activators , which are very efficient in restoring the blood flow . they can convert plasminogen into plasmin and thus degrade fibrin . despite the widespread use of established thrombolytic agents such as streptokinase , t - pa and u - pa , all these agents suffer from a number of inadequacies including resistance to reperfusion , occurrence of coronary reocclusion and bleeding complications
介绍了国内外溶栓剂蛋白质工程方面的新进展，主要涉及了组织型纤溶酶原激活剂t - pa尿激酶型纤溶酶原激活剂u - pa链激酶sk葡萄球菌激酶sak dspa及tsv - pa的研究进展。 |
